Market Closed -
Nyse
16:00:02 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
4.9
USD
|
+3.59%
|
|
+12.90%
|
+195.18%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,485
|
1,550
|
306.9
|
134.1
|
405.8
|
-
|
-
|
Enterprise Value (EV)
1 |
2,087
|
1,092
|
90.22
|
-20.12
|
464.2
|
459.3
|
405.8
|
P/E ratio
|
-8.49
x
|
-6.73
x
|
-1.93
x
|
-0.56
x
|
-2.28
x
|
-2.74
x
|
-3.65
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
45.7
x
|
1.46
x
|
1.93
x
|
5.01
x
|
4.3
x
|
2.78
x
|
EV / Revenue
|
-
|
32.2
x
|
0.43
x
|
-0.29
x
|
5.74
x
|
4.87
x
|
2.78
x
|
EV / EBITDA
|
-11,628,787
x
|
-5,497,765
x
|
-1,253,468
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-4.61
x
|
-0.66
x
|
0.17
x
|
-4.17
x
|
-5.16
x
|
-22.7
x
|
FCF Yield
|
-
|
-21.7%
|
-152%
|
606%
|
-24%
|
-19.4%
|
-4.41%
|
Price to Book
|
7.32
x
|
9.34
x
|
3.49
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
77,619
|
76,754
|
79,934
|
80,781
|
82,814
|
-
|
-
|
Reference price
2 |
32.01
|
20.20
|
3.840
|
1.660
|
4.900
|
4.900
|
4.900
|
Announcement Date
|
21-03-18
|
22-03-03
|
23-02-28
|
24-03-13
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.34
|
-
|
33.92
|
209.9
|
69.56
|
80.92
|
94.29
|
145.7
|
EBITDA
|
-
|
-179.5
|
-198.6
|
-71.98
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-219.3
|
-261.7
|
-123.6
|
-166
|
-157.9
|
-148.2
|
-118.7
|
Operating Margin
|
-
|
-
|
-771.65%
|
-58.9%
|
-238.63%
|
-195.16%
|
-157.14%
|
-81.47%
|
Earnings before Tax (EBT)
1 |
-
|
-246
|
-251.5
|
-154.7
|
-195.4
|
-175.5
|
-162.1
|
-134.9
|
Net income
1 |
-
|
-246.3
|
-230
|
-155.8
|
-240.1
|
-183.1
|
-171
|
-134.9
|
Net margin
|
-
|
-
|
-678.2%
|
-74.22%
|
-345.11%
|
-226.22%
|
-181.32%
|
-92.52%
|
EPS
2 |
-2.360
|
-3.770
|
-3.000
|
-1.990
|
-2.940
|
-2.150
|
-1.785
|
-1.342
|
Free Cash Flow
1 |
-
|
-
|
-236.8
|
-137.4
|
-121.9
|
-111.2
|
-89.05
|
-17.9
|
FCF margin
|
-
|
-
|
-698.2%
|
-65.44%
|
-175.25%
|
-137.47%
|
-94.44%
|
-12.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-04-24
|
21-03-18
|
22-03-03
|
23-02-28
|
24-03-13
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
13.15
|
17.01
|
46.5
|
17.29
|
76.32
|
69.8
|
18.99
|
19.28
|
14.49
|
16.79
|
18.12
|
19.25
|
20.37
|
21.02
|
EBITDA
|
-57.13
|
-15.49
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-57.79
|
-62.78
|
-40.36
|
-69.41
|
-3.114
|
-10.74
|
-51.57
|
-39.79
|
-37.4
|
-39.98
|
-39.95
|
-39.64
|
-39.24
|
-39.15
|
Operating Margin
|
-439.58%
|
-369.08%
|
-86.81%
|
-401.43%
|
-4.08%
|
-15.38%
|
-271.55%
|
-206.34%
|
-258.08%
|
-238.11%
|
-220.44%
|
-205.96%
|
-192.67%
|
-186.25%
|
Earnings before Tax (EBT)
1 |
-71.4
|
-56.35
|
-17.83
|
-65.32
|
-51.32
|
-20.19
|
-59.69
|
-53.73
|
-47.89
|
-39.87
|
-44.26
|
-44.07
|
-43.7
|
-43.73
|
Net income
1 |
-71.55
|
-34.38
|
-16.66
|
-64.37
|
-50.61
|
-24.16
|
-59.43
|
-47.12
|
-47.81
|
-85.03
|
-46.26
|
-46.07
|
-45.37
|
-45.4
|
Net margin
|
-544.22%
|
-202.12%
|
-35.83%
|
-372.3%
|
-66.31%
|
-34.61%
|
-312.9%
|
-244.34%
|
-329.86%
|
-506.44%
|
-255.27%
|
-239.35%
|
-222.77%
|
-215.98%
|
EPS
2 |
-0.9300
|
-0.4500
|
-0.2200
|
-0.8400
|
-0.6500
|
-0.3000
|
-0.7400
|
-0.5800
|
-0.5800
|
-1.030
|
-0.5558
|
-0.5521
|
-0.5311
|
-0.5116
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-02
|
22-03-03
|
22-05-09
|
22-08-09
|
22-11-08
|
23-02-28
|
23-05-09
|
23-08-08
|
23-11-07
|
24-03-13
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
58.4
|
53.5
|
-
|
Net Cash position
1 |
-
|
397
|
459
|
217
|
154
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-237
|
-137
|
-122
|
-111
|
-89.1
|
-17.9
|
ROE (net income / shareholders' equity)
|
-
|
-110%
|
-91.7%
|
-122%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-27.2%
|
-43.9%
|
-81.1%
|
-106%
|
-
|
Assets
1 |
-
|
-
|
-
|
573.6
|
546.5
|
225.7
|
162
|
-
|
Book Value Per Share
|
-
|
4.370
|
2.160
|
1.100
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-2.580
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.8
|
3.43
|
0.58
|
3.22
|
2.65
|
2
|
3.1
|
Capex / Sales
|
-
|
-
|
10.11%
|
0.27%
|
4.62%
|
3.27%
|
2.12%
|
2.13%
|
Announcement Date
|
20-04-24
|
21-03-18
|
22-03-03
|
23-02-28
|
24-03-13
|
-
|
-
|
-
|
Average target price
10.2
USD Spread / Average Target +108.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +195.18% | 406M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|